Today: 30 April 2026
Exxon stock price: XTO’s Eagle Ford sale push puts XOM in play ahead of key week
24 January 2026
2 mins read

Exxon stock price: XTO’s Eagle Ford sale push puts XOM in play ahead of key week

New York, Jan 24, 2026, 10:18 (EST) — The market has closed.

Exxon Mobil shares ended Friday roughly 1% higher at $134.97. Late in the session, the company confirmed that its XTO unit has opened a virtual data room to gauge buyer interest in select Eagle Ford shale assets in South Texas. Sources say the sale process is being handled internally, without investment banks. The package covers about 168,000 net acres and more than a thousand wells, with a potential value topping $1 billion. Exxon said this aligns with its ongoing strategy to “continually evaluate and optimize” its portfolio, focusing on growth in the Permian Basin, Guyana, and liquefied natural gas (LNG). Reuters

The marketing push comes at a tricky time for energy investors. Oil prices have been volatile, reacting sharply to policy updates and supply hiccups. Traders are quick to hit anything suggesting rising costs or weaker returns.

As U.S. markets remain closed for the weekend, all eyes shift to Monday’s open and a packed schedule for crude and energy stocks. The key issue: is Exxon trimming its holdings cautiously, or is this a hint at bigger shifts in its U.S. shale strategy?

A “data room” is a secure online vault containing well files, production data, and contracts that bidders sift through before submitting offers. “Non-operated” interests refer to stakes where Exxon holds a share, but another company manages the wells.

Oil prices gave energy stocks a lift late Friday. Brent ended the day at $65.88 a barrel, up 2.8%, while U.S. West Texas Intermediate (WTI) climbed 2.9% to $61.07. The gains came as Washington ramped up pressure on Iran and Kazakhstan’s Tengiz oil supply remained offline; Chevron confirmed output there hadn’t resumed following a fire. This rebound reversed a roughly 2% drop from the previous day, when tariff and military threat talk cooled off.

Weather risk is factoring in. A winter storm named Fern has already caused crude and gas shut-ins across major U.S. basins. Energy Aspects analysts put total crude losses near 300,000 barrels per day. Distillate markets have tightened as cold weather drives up demand. “There is the potential for a surge in distillate demand,” said veteran oil analyst Tom Kloza. Reuters

Supply discipline is still in play. Baker Hughes reported the U.S. oil and gas rig count ticked up by one this week, reaching 544. That’s down 32 rigs compared to a year ago, showing producers aren’t scrambling to ramp up despite crude’s recent price jumps.

Yet the weekend story could shift quickly. Should the Eagle Ford sale attract limited interest or bids below the rumored $1 billion-plus price tag, the “portfolio cleanup” story would lose steam, leaving oil prices to do the heavy lifting for the stock.

At the start of the week, XOM is set to move in line with crude, as investors await more details on the timing and terms of the Eagle Ford package. Near-term market action will hinge on winter outages, concerns over Iran’s supply, and the restart of Kazakhstan’s Tengiz field.

Exxon plans to release its fourth-quarter 2025 earnings around 5:30 a.m. CT on Friday, Jan. 30. The results will be posted on its website and filed in an 8-K.

Stock Market Today

  • Biogen Shares Rise 6% After Q1 Earnings Beat Despite Guidance Cut
    April 29, 2026, 9:29 PM EDT. Biogen (NASDAQ: BIIB) shares rose 6% on Wednesday following its first-quarter 2026 earnings report. The biotech posted $2.48 billion in revenue, surpassing analyst expectations of $2.25 billion. Net income, excluding accounting standards (GAAP), increased 19% to over $529 million, or $3.57 per share, above forecasts of $2.95. Growth was driven by strong sales of Leqembi, for early Alzheimer's, up 74%, and the FDA-approved Skyclarys for Friedreich's ataxia. However, Biogen cut full-year adjusted net income guidance by $1 per share citing research and development charges. Revenue is expected to decline mid-single digits from 2025, excluding a pending $5.6 billion acquisition of Apellis Pharmaceuticals. Biogen's strategic shift towards high-potential therapies is underway despite cautious outlook.

Latest article

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

30 April 2026
Soluna Holdings filed to register the resale of about 2.46 million common shares, with no proceeds going to the company. The move follows Sazmining’s launch of a 3-megawatt Bitcoin mining operation at Soluna’s Project Dorothy 1B in West Texas. Soluna shares last traded at $1.28, up from a $1.08 Nasdaq sale price on April 28. The registered shares include 2.4 million issuable to YA II PN, LTD. via warrant exercise.
Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

30 April 2026
Brookfield Renewable Corp’s NYSE shares fell 12.5% to $35.20 on Wednesday, with volume quadrupling the three-month average ahead of first-quarter results due Friday. The drop came despite a higher quarterly dividend and mixed analyst views. The company operates 47 GW of clean energy assets globally. Analysts expect a first-quarter loss of 33.92 cents per share on $1.62 billion in revenue.
Apple stock price: China discounts and India antitrust hearing put AAPL in focus before earnings week
Previous Story

Apple stock price: China discounts and India antitrust hearing put AAPL in focus before earnings week

ASML stock price: What to watch before Jan. 28 earnings after Intel jolts chip mood
Next Story

ASML stock price: What to watch before Jan. 28 earnings after Intel jolts chip mood

Go toTop